Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.63 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.54 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.54 |
| ▸ | PI4KA | P42356 | 2/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30544745 | 0.99 | ADORA2A (0.65) | ADORA2ATLR7ADORA1ADORA2BADCY5 | |
| SCHEMBL11350024 | 0.85 | ADORA2A (0.59) | ADORA2ATLR7ADORA1ADORA2BADCY5 | |
| SCHEMBL11222112 | 0.80 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL26981114 | 0.79 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL1532103 | 0.79 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL67131 | 0.79 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL2638945 | 0.79 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL3957869 | 0.79 | ADORA2A (0.60) | ADORA2ATLR7ADORA1ADORA2BADCY5 | |
| SCHEMBL16751826 | 0.79 | ADORA2A (0.54) | ADORA2ATLR7ADORA1ADORA2BADCY5 | |
| SCHEMBL1074972 | 0.78 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADCY5PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535597-B2 | Photoreactive ligands and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| US-20200071277-A1 | PHOTOREACTIVE LIGANDS AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535597-B2 | Photoreactive ligands and uses thereof | CLTB, CRYAB, CRYAA | ADORA2A 3376/4885TLR7 4162/4885ADORA1 4502/4885 |
| US-20200071277-A1 | PHOTOREACTIVE LIGANDS AND USES THEREOF | CLTB, CRYAB, CRYAA | ADORA2A 3376/4885TLR7 4162/4885ADORA1 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.